MedLife announces the financial results for the first nine months of 2025. The Group recorded a pro-forma consolidated turnover of over RON 2.36 billion, up 19.5 percent compared to the same period of 2024. Also, pro-forma EBITDA registered an important advance, standing 20.4 percent above the level reported in the first nine months of last year.

The most important advances were recorded on the divisions of hospitals (+39.2 percent) and clinics (+19.2 percent), followed by laboratories (+16.1 percent) and pharmacies (+11.2 percent).

The Group has accelerated the development and implementation of its own AI-based solutions aimed at supporting the advanced analysis of medical images and data. These projects contribute to increasing the accuracy of the diagnosis, the safety of the medical act and the reduction of the response time for patients.

“The results of the first nine months confirm that our growth model is solid and sustainable, even in a more moderate economic environment. The investments we make in technology, automation, genetics and artificial intelligence are not just expenses, but strategic assets that will generate value in the coming years. The data we report today reflects the transformation we are building: we are moving from screening and treatment medical services to personalized health plans, based on accurate data provided by genetics, state-of-the-art technology and the expertise of our multidisciplinary medical teams – a model that differentiates us in the long term and strengthens our competitive advantage” said Mihai Marcu, President and CEO of MedLife Group.